NovoFocus™ NSCLC 2.0 Test is a next generation sequencing (NGS)-based assay that analyzes 47 genes related to Non-Small Cell Lung Cancer (NSCLC) for clinically important alterations at the DNA level. These genes are known to be relevant for the diagnosis and/or treatment of various NSCLC according to National Comprehensive Cancer Network (NCCN) guideline and the medical literature.
|NovoFocus™ NSCLC 2.0|
|Cancer Type||Non-Small Cell Lung Cancer|
|Sample Type||FFPE Blood/Pasma (Extracted DNA)|
|Turnaround Time||14 Calendar Days|
NovoFocus™ NSCLC 2.0 interrogates the complete coding region of 47 genes and introns of 9 genes. It can detect all four types of genomic abnormalities (SNV, InDel, CNV and fusion) and provide targeted therapy options. Besides, it analyzes pharmacogenomics and provides chemotherapy options.
Comprehensive analytical validation has been completed ant the test includes rigorous quality control measures.
With leading-edge sequencing solutions and superior process efficiency, Novogene offers highly competitive prices for all our service.
Who Benefits from NovoFocus™ NSCLC 2.0?
NovoFocus™ NSCLC 2.0 is suitable for all NSCLC patients, especially for the following:
- Patients newly diagnosed with Non-Small Cell Lung Cancer (NSCLC)
- NSCLC patients with drug resistance to multiple types of chemotherapy
- NSCLC patients planning to use targeted therapy
- NSCLC patients who are treated with chemotherapies and would like to know the efficacy and toxicity of these drugs
What Clinical Information Does NovoFocus™ NSCLC 2.0 Provide?
Provides the information regarding relevant biomarkers and genomic alterations to help match patients to targeted therapies.
Provides the SNP information related to efficacy and toxicity of chemotherapies.
|47 genes on targeted therapy|
|9 genes on chemotherapy|